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ABSTRACT
Hepatocellular carcinoma (HCC) is the sixth most frequently diagnosed malignancy in the world, with the num-
ber of cases steadily increasing. Currently, around 850,000 new cases are diagnosed annually. In the majority 
of patients, HCC is diagnosed at an advanced stage mainly due to the lack of early symptoms. Risk factors for 
HCC are well known. HCC usually develops in cirrhotic liver; the exception is a form of fibrolamellar carcinoma 
arising in healthy liver. Hepatocarcinogenesis is a multistage process in which many pathways of intracellular 
signal transduction are disturbed, which leads to various biological characteristics of the disease. During foetal 
life, liver cells produce multiple factors, e.g. epidermal growth factor (EGF), vascular endothelial growth factor 
(VEGF), or platelet-derived growth factor (PDGF), which play a significant role in organogenesis. In adults, the 
production of many of the factors decreases or does not exist. As a result of organ damage (e.g. after injury), 
hepatocytes start the synthesis again, but only temporarily. In a chronically damaged liver, a dysregulation of 
the production of these factors takes place, it is continuous and leads to hepatocarcinogenesis. Understanding 
the HCC pathogenesis has allowed the synthesis of compounds that can directly interfere with the molecular 
pathways associated with the growth and progression of tumours. Cabozantinib (an oral tyrosine kinase inhibitor) 
targets VEGF, MET, and AXL receptors. It may be an option in patients with HCC with disease progression after 
one or two lines of systemic treatment (e.g. after sorafenib therapy). The use of cabozantinib in the treatment of 
patients with advanced HCC was evaluated in a prospective phase III study, which demonstrated prolongation 
of overall survival (OS) and progression-free survival (PFS) compared to patients receiving placebo. Based on 
the results of the study, the use of cabozantinib provides an opportunity to further improve treatment outcomes 
in patients with advanced HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the most com-
mon primary liver cancer. Hepatocarcinogenesis is 
a complex, multistage process, in which the disorders 
of many intracellular transduction pathways occur, 
subsequently leading to heterogenous biological 
characteristics of the disease. During foetal life, many 
growth factors are produced by hepatocytes and this 
plays a significant role in organogenesis — these are 
epidermal growth factor (EGF), insulin-like growth 
factors (IGF), hepatocyte growth factor (HGF), vas-
cular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF), platelet-derived growth factor 
(PDGF), and transforming growth factor-a and -b 
(TGF-a, -b). In the healthy liver of an adult human the 
production of many of them is reduced to a minimum 
or does not exist. In turn, when regenerative processes 
after organ damage (e.g. injury) require the produc-
tion of these factors, adult hepatocytes synthesise 
them for a transitional period (EGF, TGF-a, IGF, 
and VEGF). However, this process is dysregulated 
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in chronically damaged liver, leading to permanent 
mitogenic signalling. Like other growth factors (FGF, 
PDGF), HGF is produced and released from sources 
other than hepatocytes (e.g. activated hepatic stellate 
cells, myofibroblasts, endothelial cells, Kupffer cells, 
and bile duct epithelium), which can contribute to 
hepatocarcinogenesis. There is no single dominant 
signal pathway in the pathogenesis of HCC; however, 
the introduction of molecular target-directed drugs 
(targeted therapies) significantly expanded the possi-
bilities of systemic therapy of patients with HCC [1, 2].
The first drug with documented impact to extend 
overall survival (OS) in patients with HCC in advanced 
clinical stages was sorafenib, a small-molecule multi-
kinase inhibitor. Clinical efficacy has also been con-
firmed for regorafenib in the second-line treatment. 
Regorafenib has molecular targets similar to sorafenib 
— in patients with advanced HCC after sorafenib failure 
it showed a significant prolongation of OS by almost 
three months compared to the control group. 
A novel drug with proven effectiveness in the treat-
ment patients with HCC is cabozantinib, an oral tyrosine 
kinase inhibitor targeted against VEGFR, MET, and 
AXL. Cabozantinib is indicated for use as monotherapy 
in adult patients with HCC previously treated with 
sorafenib. The aim of the study is to present the value 
of cabozantinib in patients with advanced HCC.
Epidemiology
The most common primary liver cancer is HCC 
(approximately 85–90%), which accounts for about 4% 
of all newly diagnosed cancers in the world and is the 
sixth cancer in terms of prevalence worldwide (about 
850,000 new cases annually) and the tenth cause of 
cancer-related deaths. HCC morbidity is constantly 
increasing. Gender diversity is observed — HCC ap-
plies more than twice as much to men than to women. 
In Poland about 3000 new cases are diagnosed annu-
ally. Unlike other human malignancies, risk factors 
for HCC are well understood [2–7]. There is also clear 
geographical differentiation of HCC, which is undoubt-
edly related with exposure to hepatitis B (HBV) and 
C virus (HCV) infections. More than 80% of all HCC 
cases occur in developing countries, mainly in China and 
Southeast Asian countries and in sub-Saharan Africa. In 
Western countries the incidence of HCC is low except 
for in Southern Europe, where morbidity among men 
is higher.
The risk of developing HCC increases with age. The 
highest incidence is observed in people aged around 
50–60 years, but some young people at the age of 
20–30 years are also affected; they have a rarely occur-
ring form of so-called fibrolamellar carcinoma (FLC).
Aetiology
In 70–90% of cases, HCC develops on the grounds 
of liver cirrhosis, caused by chronic hepatotropic virus 
infection (HBV, HCV) or toxic liver damage (alcohol, 
nonalcoholic fatty liver disease [NAFLD], aflatoxin 
— produced by Aspergillus flavus), and it is seen much less 
often metabolic diseases (especially hemochromatosis 
— about 300-fold increased risk of HCC) and alpha-1 an-
titrypsin deficiency. Other factors that increase HCC 
risk are associated with obesity and insulin resistance. 
Research is currently underway to determine the impact 
of genetic disorders on HCC development. Mutations, 
translocations, amplifications, deletions within suppres-
sor genes (TP53, DLC1, Wnt pathway), oncogenes and 
growth factors (EGFR, VEGFR, Ras, mTOR pathway, 
HEDGEHOG, HGF, IGF), and cell cycle regulators 
(cyclin-dependent kinase inhibitor 2A [p16] or cell cycle 
regulator p27). Understanding genetic disorders allows 
the use of targeted therapies. The targets for molecular 
drugs are intracellular signalling pathways responsible for 
cell proliferation and tumour growth, but also influencing 
tumour angiogenesis and dissemination [1, 7, 8].
HCC development is a complicated, multistage 
process. A transformation from a regenerative nodule 
into cirrhosis, through the dysplastic nodule, to cancer 
usually takes many months. Enlarging the lesion to about 
2 cm in diameter takes about 12 months [9–11].
Pathology
Hepatocellular cancer is adenocarcinoma in 
a single-focal, multifocal, or disseminated infiltration 
form. It can have various degrees of histological ma-
turity — from G1 (reminiscent of normal hepatocytes) 
to G4 (undifferentiated). FLC is a specific type, found 
mainly in young people, with no relation to cirrhosis, 
appearing in unchanged liver without connection to 
viral infection, and characterised by increased AFP 
serum concentration.
Diagnostics
Symptoms
Early HCC symptoms are unspecific. They may re-
sult from coexisting liver cirrhosis. The course of liver 
cirrhosis in compensated phase may be asymptomatic 
or minimal symptoms may be found. General symp-
toms include: asthaenia, loss of appetite, weight loss, 
low-grade fever, nausea, vomiting, diarrhoea, and pain 
in the right subcostal region of the abdomen or epigas-
trium. The liver can be enlarged, hard, painless, and with 
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nodular changes. Increasing portal hypertension leads 
to development of collateral circulation, oesophageal 
varices, haemorrhoids, and characteristic “Medusa’s 
head” (widened capillary network in the chest and 
abdominal wall). Impairment of hepatic function can 
lead to thromboembolic complications or haemorrhagic 
diathesis. The symptoms may also include jaundice, 
ascites, or encephalopathy in advanced states. In the 
course of HCC, symptoms of paraneoplastic syndromes 
can occur: dermatomyositis syndromes, gynecomastia, 
polyglobulia, hypercalcaemia, hypercholesterolaemia, 
hypoglycaemia, or dysfibrinogenaemia [10, 12].
Laboratory tests 
In patients with HCC, abnormal results of labora-
tory tests are observed. In the complete blood count 
(CBC) some features of anaemia are observed, as well 
as thrombocytopaenia, that can transform into throm-
bocythaemia. Coagulation system disorders are also 
present (reduced prothrombin plasma level, prolonged 
activated partial thromboplastin time [APTT]), as well 
as disorders of lipid (hypocholesterolaemia, sometimes 
leading to hypercholesterolaemia) and protein (hy-
poalbuminaemia, reduced total protein plasma level) 
metabolism. Hyperbilirubinaemia is observed, increased 
aminotransferase levels with common predominance 
of aspartate aminotransferase (AST) over alanine 
aminotransferase (ALT) — de Ritis ratio > 1, glucose 
intolerance or type 2 diabetes, and, rarely, hepatorenal 
syndrome (HRS).
The only serological marker used in HCC diagnosis 
is AFP serum concentration [10, 12]. The value of AFP 
does not show a close relationship with HCC stage. In 
a significant group of patients with HCC, an increased 
AFP (a-fetoprotein) concentration is observed, but in 
approximately 40% of patients there is no increase in 
the concentration of this protein. About 30% of patients 
with cirrhosis may have an elevated AFP concentration 
without HCC. In patients with FLC the concentration 
of AFP may be normal.
Non-invasive diagnostics
In the majority of patients the diagnosis of HCC 
is based on imaging examinations. The most com-
monly used method in the initial diagnosis, especially 
in surveillance of patients with cirrhosis, is abdominal 
ultrasound examination (USG). The sensitivity of this 
method ranges between 65 and 80%, and the specific-
ity is above 90%. The basic diagnostic methods include 
three-phase computed tomography (CT) examination 
with contrast medium and magnetic resonance imaging 
(MRI). The radiological picture is characteristic: there 
is contrast enhancement in the arterial phase of the 
study and delayed contrast washout during venous and 
delayed phases. According to the guidelines, a typical 
radiological image justifies HCC diagnosis without 
histopathological examination [13–15].
Positron emission tomography (PET) in combination 
with CT (PET-CT) is not recommended for recognition 
of early cancer forms but may be useful in later stages 
to exclude a retrohepatic tumour location.
Invasive diagnostics 
HCC diagnosis is based on histological or — less 
valuable — cytological examination. As recommended 
by experts and European guidelines (EASL 2018 guide-
lines), in the case of cirrhotic liver with nodule below 
1 cm, which neither changes its nature nor grows, ab-
dominal USG should be repeated every four months. If 
the tumour grows to a diameter of 1–2 cm, detailed 
imaging diagnostics (CT, MRI) should be performed. 
A change of 1–2 cm requires confirmation in two imag-
ing tests with contrast. In the case of nodules greater 
than 2 cm, a typical radiological image (as described 
above) in a single imaging study is sufficient to diag-
nose HCC.
Clinical staging of HCC helps in selecting the opti-
mal treatment strategy. In addition to the need to per-
form imaging tests, it is also required to assess patient’s 
performance status (PS) and liver function. There are 
several systems for HCC clinical classification. The TNM 
classification only assesses the stage of the disease and 
does not take into account the accompanying hepatic 
impairment according to Child-Pugh scale. Okuda stag-
ing system (Okuda’s scale), including information about 
tumour and liver function, is currently rarely used. In 
Europe the most popular classification is the Barcelona 
Clinic Liver Cancer (BCLC) staging system, which 
assesses all of aforementioned factors (tumour stage, 
liver efficiency according to the Child-Pugh scale, and 
PS). The BCLC classification divides patients into five 
categories (0, A, B, C, and D). The BCLC division is 
helpful when assessing patients’ eligibility for treatment 
[3, 4, 13, 16–18].
Surgical treatment
Eligibility criteria of HCC patients for surgical 
treatment and transplantation are highly restrictive but 
give a chance of a complete cure. Cancer resection in 
cirrhotic liver may be considered in patients with BCLC 
stage 0 or A. In patients without cirrhosis, surgery is 
the treatment of choice because the resection of even 
a large volume of the organ does not put the patient at 
risk of liver failure. Classical eligibility criteria for liver 
transplantation in patients with HCC are the so-called 
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Milan criteria: patients with one nodular change in 
the liver less than 5 cm or a maximum of three lesions 
in the liver not exceeding 3 cm can be qualified for 
transplantation. In practice, extended criteria are often 
used, the so-called “up to seven” criterion — the size 
of the largest lesion expressed in centimetres and the 
number of remaining lesions summed to a maximum 
of seven [13, 19–21].
Local methods of treatment
In a properly selected group of patients with recur-
rent diseases after surgery or ineligible for resection or 
transplantation a significant improvement of prognosis, 
and even long-term remission, can be obtained using lo-
cal methods of treatment, which include: radiofrequency 
ablation (RFA), percutaneous ethanol injection therapy 
(PEIT), radioembolisation, transarterial embolisation 
(TAE), or cryoablation [22–24].
Systemic treatment
Advances in understanding the pathogenesis of 
HCC have led to the development of drugs that can 
interfere directly with the molecular pathways associ-
ated with cancer growth and progression. Sorafenib 
has proven impact on OS in HCC patients; it is an oral 
small-molecule inhibitor of many tyrosine kinases (Raf, 
VEGFR, PDGR-b, KIT, FTL-3, RET) and is charac-
terised by anti-angiogenic and anti-proliferative activity. 
The basis for the registration of sorafenib for use in HCC 
treatment was an international, multi-centre phase III 
clinical trial with the acronym SHARP (Sorafenib Hepa-
tocellular Carcinoma Assessment Randomised Proto-
col). The results of the study showed a significant OS 
improvement in HCC patients treated with sorafenib, 
compared to the placebo group. In total, 602 patients 
with advanced HCC were enrolled in the study (ap-
proximately 90% from European sites). Treatment 
with sorafenib was rarely associated with an objective 
response to treatment – the partial response (PR) rate 
was seen in 2.3% of patients only; more often stabilisa-
tion of the disease (SD) was observed (about 71%). The 
median OS in sorafenib patients was 10.7 months, that 
is almost three months longer than in the control group 
[25, 26]. In another phase III clinical trial with similar 
design to the SHARP study, the efficacy of sorafenib in 
the Asian population was evaluated; a significant reduc-
tion of the disease progression risk (by 42%) and risk 
of death (by 33%) were observed. Note the difference 
in statistical power of both studies and the difference 
in the aetiology of HCC — in the Asian study patients 
with hepatitis B virus (HBV) constituted about 75% of 
the study population, while in the European study it was 
about 30% of patients. The Asian study also included 
patients in a worse general condition and with more 
advanced HCC compared to the European study; hence, 
both prognosis and treatment results in Asian countries 
were generally worse [27, 28]. In Poland, sorafenib 
is reimbursed within a drug program. This agent is 
indicated in the treatment of patients with HCC with 
advanced disease, which prevents surgical treatment of 
patients with relapse after radical surgery, after failure 
of previously used local treatment methods, or when 
they are unavailable.
Another option of systemic treatment of patients 
with HCC is regorafenib, which is a multi-kinase in-
hibitor with similar molecular targets to sorafenib (the 
structure differs only by one substituent). Regorafenib 
is indicated for second-line treatment in patients with 
advanced HCC, who received sorafenib in the first-line 
therapy with good clinical tolerance but, progression 
of the disease was found after a beneficial period. In 
a clinical trial regorafenib was compared with placebo, 
and OS was the main efficacy outcome assessed. Re-
gorafenib was shown to prolong the OS — the median 
was 10.6 months, compared with 7.8 months in placebo 
group [29]. Currently in Poland regorafenib treatment 
is not reimbursed.
A new drug with proven efficacy targeting the mo-
lecular pathways associated with tumour growth and 
HCC progression is cabozantinib [30, 31]. Cabozantinib 
may be considered in patients with disease progression, 
who have received one or two systemic treatment lines 
and have normal liver function and performance status 
0–1 according to the Eastern Cooperative Oncology 
Group (ECOG) scale. On November 12, 2018, the Euro-
pean Medicines Agency (EMA) approved cabozantinib 
for use as monotherapy in the treatment of adult HCC 
patients who had previously received sorafenib.
Cabozantinib is an oral non-selective, multi-kinase 
inhibitor directed against VEGF receptor type 2 (VEG-
FR2), the mesenchymal epithelial transition factor recep-
tor (Met), and AXL receptor tyrosine kinase (Fig. 1) 
[32, 33]. Through the inhibition of tyrosine kinases, 
cabozantinib affects processes associated with tumour 
growth, angiogenesis, metastasis, bone remodelling, and 
drug resistance. Effects on VEGF pathway are a known 
therapeutic target in HCC, but clinical benefits are 
inadequate. Inhibition of additional intracellular trans-
mission pathways can successfully improve the effective-
ness of treatment. Similarly to VEGR, the MET and 
AXL tyrosine kinase receptors are induced by tumour 
hypoxia and play an important role in tumour biology. 
The dysregulation of HGF/cMET pathway receptors is 
crucial for hepatocyte regeneration after liver injury. 
Both kinases are also involved in the development of 
resistance to anti-angiogenic therapies. High MET and 
199
Ewa Klank-Sokołowska et al., Cabozantinib in the treatment of advanced hepatocellular carcinoma patients
AXL expression may be associated with poor prognosis 
in HCC patients.
In a phase II randomised clinical trial, cabozantinib 
showed clinical activity in patients with advanced HCC, 
and the results were independent of previous treatment 
(prior sorafenib use — yes or no). The median OS was 
11.5 months, and the median progression-free survival 
(PFS) reached 5.2 months.
Based on the aforementioned results, a phase III 
double-blind, randomised, placebo-controlled study 
(CELESTIAL) was performed. Recruitment for the 
study was conducted in 19 countries from September 
2013 to September 2017. The study included 707 patients 
with advanced HCC, who were ineligible for radical 
treatment and had previously received sorafenib in 
first-line treatment. Inclusion criteria were as follows: 
age over 18 years, ECOG performance status 0–1, 
Child-Pugh class A, normal kidney function, and absence 
of abnormalities in haematopoietic function. Patients 
were allowed to receive one previous treatment line 
— apart from sorafenib — due to advanced disease. 
Patients were randomly assigned (2: 1) to a group receiv-
ing cabozantinib (n = 470) or a group receiving placebo 
(n = 237). Randomisation was stratified according to 
the aetiological factor (HBV with or without HCV, 
HCV — without HBV, or other), geographical region 
(Asia or other region), and the presence of extrahepatic 
metastases and infiltration of large blood vessels. Cabo-
zantinib was administered orally at a daily dose of 60 mg. 
A treatment disruption or dose reduction to 40 mg and 
20 mg was used to control side effects. Treatment was 
continued until patients had clinical benefit or until un-
acceptable toxicity occurred. OS was a primary endpoint, 
and the secondary endpoints included PFS and overall 
response rate (ORR). The response was assessed based 
on CT according to RECIST 1.1 criteria every eight 
weeks, and patients were allowed to continue blinded 
treatment after radiological disease progression as long 
as they had clinical benefit. Based on the data analysis, 
it was found that the median OS in the cabozantinib 
group was 10.2 months (95% CI [confidence interval]: 
9.1–12.0 months) and 8.0 months in the placebo group 
(95% CI: 6.8–9.4 months). The risk of death decreased 
by 24% (hazard ratio [HR] = 0.76; 95% CI: 0.63–0.92; 
p = 0.005). The median PFS in cabozantinib group was 
5.2 months (95% CI: 4.0–5.5 months) and 1.9 months 
in the placebo group (95% CI: 1.9 months). The risk 
of disease progression decreased by 56% (HR = 0.44, 
95% CI: 0.36–0.52, p < 0.001). Objective response 
rate according to RECIST 1.1 criteria was 4% in the 
cabozantinib group (18 out of 470 patients achieved 
PR) and less than 1% in the placebo group (one out 
of 237 patients). Disease control (PR and SD) was 
achieved in 64% of patients treated with cabozantinib 
(n = 300) compared with 33% (n = 79) in the placebo 
group. In the CELESTIAL clinical trial, the mean 
treatment duration was 3.8 months in the cabozantinib 
group and two months in the placebo group. The dose 
was reduced in 62% of patients receiving cabozantinib 
(n = 291) and in 13% in the placebo group (n = 30). The 
average daily dose of cabozantinib was 35.8 mg, and in 
the placebo group it was 58.9 mg, with median time to 
GAS6 HGF VEGF 
Proliferation, apoptosis, angiogenesis, metastases
AXL c-MET VEGFR Extracellular domain
Intracellular domain
PI3K RAS
RAF
MEK
ERG
AKT JAK 
mTOR STAT 
Gene transcription
Figure 1. Mechanism of action of cabozantinib
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first dose reduction of 38 days, and to first disruption of 
cabozantinib treatment — 28 days. The majority of com-
plications observed with cabozantinib were analogous 
to the adverse effects profile observed during treatment 
with other tyrosine kinase inhibitors with anti-VEGFR 
activity. The incidence of adverse events (AEs) of any 
degree was high, e.g. 99% vs. 92%, of which there were 
68% and 36% grade 3 and 4 AEs, respectively. The most 
common grade 3 and 4 adverse events in the cabozan-
tinib group were: hand-foot syndrome (palmar-plantar 
erythrodysesthesia [PPE]) — 17% vs. 0%, hypertension 
— 16% vs. 2%, increased transaminases activity — 12% 
vs. 7%, fatigue — 10% vs. 4%, diarrhoea — 10% vs. 2% 
[34]. The most frequent cause of dose reduction in pa-
tients receiving cabozantinib was PPE (22%), diarrhoea 
(10%), fatigue (7%), hypertension (7%), and elevated 
transaminases (6%).
In conclusion, cabozantinib therapy in patients 
previously treated systemically due to advanced HCC 
resulted in statistically and clinically significantly longer 
OS and PFS, compared with patients receiving placebo.
Conclusions
Significant evolution in understanding the molecular 
pathology of HCC has contributed to the develop-
ment of drugs targeted on signalling pathways [18, 35]. 
Pre-clinical and clinical trials are underway to test 
other options in HCC therapy. Recently, high hopes 
are associated with immunotherapy, used in various 
types of cancer. There are currently many clinical tri-
als evaluating the safety and efficacy of new therapies 
for the treatment of HCC, including nivolumab, pem-
brolizumab, tremelimumab, and lenvatinib [36–39]. It 
seems that in the near future this may translate into an 
improvement in the treatment outcomes in patients with 
advanced HCC.
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